Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474277 | 0.90 | HPGDS (0.53) | KDM4EGPR119JAK1JAK2HTR2B | |
| SCHEMBL15551483 | 0.89 | HPGDS (0.54) | KDM4EGPR119JAK1JAK2HTR2B | |
| SCHEMBL19911968 | 0.86 | JAK3 (0.45) | KDM4EGPR119JAK1JAK2JAK3 | |
| SCHEMBL19896198 | 0.86 | JAK3 (0.45) | KDM4EGPR119JAK1JAK2JAK3 | |
| SCHEMBL19896193 | 0.86 | JAK3 (0.45) | KDM4EGPR119JAK1JAK2JAK3 | |
| SCHEMBL948255 | 0.86 | GPR119 (0.53) | KDM4EGPR119JAK1JAK2HTR2B | |
| SCHEMBL27165344 | 0.83 | OXTR (0.43) | KDM4EGPR119JAK1JAK2HTR2B | |
| SCHEMBL18788557 | 0.80 | GPR119 (0.47) | KDM4EGPR119JAK1JAK2HTR2B | |
| SCHEMBL30327408 | 0.79 | HTR2B (0.48) | KDM4EJAK1HTR2BADRA1A | |
| SCHEMBL22900007 | 0.78 | HTR2B (0.43) | JAK1JAK2HTR2BJAK3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20180271837-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-09-27 | — | — | US | disclosed |
| US-8609696-B2 | Serotonin 5-HT2B receptor inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2379524-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010080357-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080357-A1 | SEROTONIN 5-HT2B RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271837-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, SLC26A3, SLC8B1 | KDM4E 3578/4885GPR119 442/4885JAK1 2906/4885 |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | HTR2B, HTR1B, HTR3B | KDM4E 3720/4885GPR119 151/4885JAK1 4223/4885 |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, SLC26A3, ALDH5A1 | KDM4E 3607/4885GPR119 488/4885JAK1 2980/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | KDM4E 1088/4885GPR119 3532/4885JAK1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.